Fulgent Genetics (NASDAQ:FLGT) Releases Earnings Results

Fulgent Genetics (NASDAQ:FLGT) posted its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.56, FiscalAI reports. Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. The company had revenue of $90.41 million for the quarter, compared to the consensus estimate of $86.30 million.

Here are the key takeaways from Fulgent Genetics’ conference call:

• Third-quarter revenue rose 8% year over year to $90.4 million, with Anatomic Pathology up 57% and BioPharma Services up 5%; growth was primarily driven by the integration of Bako and StrataDx. Precision Diagnostics declined 18% year over year.
• Management reported improving collections after billing-system customizations helped lift third-quarter revenue and gross margin sequentially. The transition is not complete, however, and management said further work is needed before collections return to historical levels.
• Fulgent narrowed its 2026 non-GAAP loss-per-share outlook to $1.65–$1.75 from $2.22–$2.35, and raised its projected year-end cash, restricted cash, and marketable securities to about $630 million. The cash increase chiefly reflects a $112.3 million federal tax refund and related interest.
• The company reported progress in its oncology pipeline: FID-007’s Phase II is mostly complete, with a Phase III study in preparation, while FID-022 is in Phase I dose escalation. These programs remain clinical-stage and their commercial prospects are uncertain.
• Fulgent’s AI platform analyzed about 255,000 slide images in Q3, up 23% sequentially, and analysis failures fell to 0.01%; five additional AI applications are planned for Q4. Management said the technology could improve quality and productivity, though it did not quantify a current financial benefit.

Fulgent Genetics Stock Up 27.2%

NASDAQ FLGT traded up $5.08 during trading hours on Friday, hitting $23.74. The company had a trading volume of 1,097,340 shares, compared to its average volume of 274,766. Fulgent Genetics has a fifty-two week low of $13.46 and a fifty-two week high of $31.04. The business has a fifty day simple moving average of $20.80 and a 200-day simple moving average of $19.31. The firm has a market cap of $653.09 million, a P/E ratio of -7.68 and a beta of 1.00.

Insiders Place Their Bets

In other news, insider Hanlin Gao sold 1,673 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.66, for a total transaction of $32,891.18. Following the completion of the transaction, the insider owned 986,117 shares of the company’s stock, valued at approximately $19,387,060.22. The trade was a 0.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,127 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.66, for a total transaction of $41,816.82. Following the transaction, the chief operating officer directly owned 359,924 shares of the company’s stock, valued at approximately $7,076,105.84. This trade represents a 0.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,932 shares of company stock worth $117,156 over the last quarter. 36.18% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Saturday. Piper Sandler raised their target price on shares of Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings upgraded Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Fulgent Genetics presently has an average rating of “Hold” and a consensus price target of $27.50.

About Fulgent Genetics

Fulgent Genetics, Inc is a technology-driven clinical diagnostics company that develops and performs genetic testing. Its testing platform uses next-generation sequencing and other molecular technologies to analyze DNA and support the diagnosis, screening and management of inherited and acquired diseases.

The company offers a range of tests, including panels for hereditary cancer, reproductive health and inherited disorders, as well as tumor profiling and other specialized clinical testing services.